Kling Douglas F

COO Kling sold 98,612 shares (69.1% of holdings) across 3 transactions for $2.1M; NAMS stock up 18.9% in 30 days

Douglas F Kling, Chief Operating Officer of NewAmsterdam Pharma (NAMS), executed 3 separate sales totaling 98,612 shares (98.6K shares) for $2,096,655.08 ($2.1M) on July 15–16, 2025, reducing his holdings by 69.1% from 142,612 to 44,000 shares. The sales occurred at a blended average price of $21.26, well below the current price of $21.98 and notably below the 52-week high of $26.61. The timing coincides with a strong 30-day rally of +18.9% and 90-day gain of +34.5%, yet the company remains unprofitable with net income of $-39,527,000.00 ($-39.5M) over its latest full fiscal year, despite rapid annual revenue growth of +223.4%. The substantial reduction in a COO's holdings during an upswing in an otherwise loss-making company merits close attention to the underlying business rationale.

COO Kling sells 100,000 shares (69.4% of holdings) for $1.9M at blended avg $19.29; stock now -31.6% from 52-week high.

Chief Operating Officer Douglas F. Kling executed two separate sales totaling 100,000 shares for $1,929,141.04 at a blended average price of $19.29 on 2025-06-16, reducing his holdings from 144,000 to 44,000 shares—a 69.4% reduction. The sales occurred as NAMS stock trades at $18.20, down 31.6% from its 52-week high of $26.61 and down 4.4% over the prior 30 days. The company remains deeply unprofitable with a net income of $-39,527,000.00 over its most recent full fiscal year, though it posted strong revenue growth of 223.4% annually. A significant reduction in insider stake by a senior executive during a period of substantial share price decline and persistent losses warrants investor attention to the company's operational trajectory and management's confidence posture.